AGIO — Agios Pharmaceuticals Share Price
Last Trade - 00:00- $2.75bn
- $1.08bn
- $78.75m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 8.25 | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 69.89 | 43.01 | 94.39 | 117.91 | 203.2 | 5.12 | 53.76 | 28.01% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.
Directors
- David Schenkein CHM (63)
- Jacqualyn Fouse CEO (59)
- Jonathan Biller CFO (57)
- Bruce Car (59)
- Christopher Bowden (59)
- Darrin Miles (47)
- John Maraganore (58)
- Paul Clancy (59)
- Ian Clark (60)
- Kaye Foster (61)
- Maykin Ho (68)
- David Scadden (68)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- August 7th, 2007
- Public Since
- July 24th, 2013
- No. of Shareholders
- 11
- No. of Employees
- 562
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 61,574,283
- Address
- 88 Sidney St, CAMBRIDGE, 02139-4137
- Web
- http://www.agios.com/
- Phone
- +1 6176498600
- Contact
- Holly Manning
- Auditors
- PricewaterhouseCoopers LLP
Latest News for AGIO
Upcoming events for AGIO
Q3 2021 Agios Pharmaceuticals Inc Earnings Release
Similar to AGIO
ACORDA THERAPEUTICS ORD
NASDAQ Global Select Market
ADAPTIMMUNE THERAPEUTI ADR REP 6 ORD
NASDAQ Global Select Market
AKERO THERAPEUTICS ORD
NASDAQ Global Select Market
AKOUOS ORD
NASDAQ Global Select Market
ALECTOR ORD
NASDAQ Global Select Market
FAQ
As of Today at 19:58 UTC, shares in Agios Pharmaceuticals are trading at $44.65. This share price information is delayed by 15 minutes.
Shares in Agios Pharmaceuticals last closed at $44.65 and the price had moved by +7.15% over the past 365 days. In terms of relative price strength the Agios Pharmaceuticals share price has underperformed the S&P500 Index by -18.71% over the past year.
The overall consensus recommendation for Agios Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Agios Pharmaceuticals does not currently pay a dividend.
Agios Pharmaceuticals does not currently pay a dividend.
Agios Pharmaceuticals does not currently pay a dividend.
To buy shares in Agios Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $44.65, shares in Agios Pharmaceuticals had a market capitalisation of $2.75bn.
Here are the trading details for Agios Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AGIO
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Agios Pharmaceuticals does not currently have a style classification.
The analyst consensus target price for shares in Agios Pharmaceuticals is $62.63. That is 40.27% above the last closing price of $44.65.
Analysts covering Agios Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $26.12 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Agios Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -22.45%.
As of the last closing price of $44.65, shares in Agios Pharmaceuticals were trading -10.64% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Agios Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 3.04. The shares last closed at $44.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Agios Pharmaceuticals' management team is headed by:
- David Schenkein - CHM
- Jacqualyn Fouse - CEO
- Jonathan Biller - CFO
- Bruce Car -
- Christopher Bowden -
- Darrin Miles -
- John Maraganore -
- Paul Clancy -
- Ian Clark -
- Kaye Foster -
- Maykin Ho -
- David Scadden -
We do not have data on Agios Pharmaceuticals' shareholders